• Recruiting

NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) NDMM

Updated: Jun 13

Multiple Myeloma Research Consortium

phase 2 study

Dara-KRd

Multiple Myeloma Research Consortium

NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma



Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma


The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.


Sponsor:

University of Chicago


Collaborators:

Janssen Scientific Affairs, LLC

Amgen


Multiple Myeloma Research Consortium

 

ClinicalTrials.gov Identifier: NCT03500445


Official Title: Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy

First Posted: April 18, 2018


Click here for details on ClinicalTrials.gov

 

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

Daratumumab : National Cancer Institute

Daratumumab : MedlinePlus Drug Information

 

Drug: Daratumumab

Drug: Carfilzomib

Drug: Lenalidomide

Drug: Dexamethasone

 

2759 A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II

Hematology Disease Topics & Pathways:

Clinical Trials, Clinical Research, Plasma Cell Disorders, Clinically Relevant, Diseases, Lymphoid Malignancies

Sunday, December 12, 2021, 6:00 PM-8:00 PM


Conclusions: The combination of Dara-KRd as extended frontline therapy for NDMM without employing ASCT can induce high rates of MRD-negativity within 8 cycles, exceeding the historical sCR rate of KRd without Dara. Importantly, the rate and depth of MRD-negativity improve beyond cycle 8, suggesting that extended Dara-KRd without ASCT may generate rates of sCR and MRD-negativity comparable to KRd with ASCT. Yearly longitudinal determinations of MRD after completion of 24 cycles of Dara-KRD protocol treatment will generate information on the durability of MRD and the role of ASCT compared to shorter treatments with Dara-KRd, with and without ASCT.

Click here for details

 

Location

United States, Illinois

Posts Archive